Retatrutide (GIP/GLP-1/glucagon) triple agonist research peptide
Retatrutide is an investigational synthetic peptide studied as a single molecule that activates three receptors: GIP, GLP-1 and glucagon. Snowman carries retatrutide powder in seven vial sizes, from 5mg to 60mg, each sealed as a lyophilized cake. Research use only; it is not an approved medicine and is never for human use. Seen it called Reta, GLP-3 or triple G? The Sema, Tirz and Reta name decoder explains each nickname.
Pick a vial size
- 5mg $35.00 USD
- 10mg $50.00 USD
- 15mg $60.00 USD
- 20mg $75.00 USD
- 30mg $110.00 USD
- 40mg $140.00 USD
- 60mg $200.00 USD
Every fill, at a glance
The glucagon receptor, briefly
Retatrutide (development code LY3437943) is one peptide that activates three receptors: those for GIP, GLP-1 and glucagon. Researchers call this a triple hormone-receptor agonist, which also makes retatrutide a glucagon receptor agonist in addition to its GIP and GLP-1 activity[1]. Compare it with tirzepatide, a dual agonist of the GIP and GLP-1 receptors only, on the tirzepatide family page.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. https://pubmed.ncbi.nlm.nih.gov/37366315/